2010 AnnuAl REpoRT - Ciberdem

The effects of metformin on cardiovascular risk factors in
prepubertal children born small for gestational age without
postnatal catch-up growth, currently treated with growth
hormone
Pfizer, PCP00046: 2009-2011
Principal Investigator: Lourdes Ibáñez
Associate investigators: Paula Casano, Marta Díaz, Carme
Valls, María Victoria Marcos
Scientific collaborations within CIBERDEM
Body fat amount and distribution in childhood determines
predisposition to type 2 diabetes
CHILDBODYFAT: 2009-2010
Coordinator: Lourdes Ibáñez
CIBERDEM groups: L Ibáñez, X Correig, L Masana
Clinical trials
Endocrine-metabolic and body composition effects of
metformin administration in prepubertal children with a
low birthweight for gestational age, postnatal catch-up
growth and risk markers for the metabolic syndrome.
Phase II
Instituto de Salud Carlos III, Fondo de Investigación
Sanitaria, EC08/00160: 2008-2010
Name of the participants: Ibáñez L (PI), Casano P, Diaz M,
Valls C, del Rio L, Marcos MV, Enríquez G, Sebastiani G,
Hollenberg G, Fortea E and Cortés R (researchers)
Cumulative gain in total and abdominal fat mass in prepubertal
girls (age ~ 8 years) with a history of low birthweight and precocious
pubarche, who were randomized to remain untreated (n=19;
open circles) or to receive metformin (n=19; closed circles) for 4 yr,
and who were then followed for 1 yr without intervention. Pubertal
metformin treatment reduced fat gain not only through puberty, but
also beyond puberty. Mean and 95% CI are shown. Difference in
rate of change between subgroups significant by repeated-measures
ANOVA. Image from: J Pediatr, 2010.
Effects of the addition of metformin to growth hormone
therapy on cardiovascular risk factors in prepubertal short
children born small for gestational age. Phase II
Instituto de Salud Carlos III, Fondo de Investigación
Sanitaria, EC10/0031: 2010-2012
Name of the participants: Casano P (PI), Ibáñez L, Diaz M
and Sebastiani G (researchers)
Ethynil-estradiol-cyproterone acetate versus low-dose
pioglitazone + flutamide + metformin in adolescents with
hyperinsulinemic ovarian hyperandrogenism: Effects on
parameters of chronic inflammation and on risk factors of
type 2 diabetes and cardiovascular risk. Phase II
Instituto de Salud Carlos III, Fondo de Investigación
Sanitaria, PI09/90444: 2009-2011
Name of the participants: Ibáñez L (PI), Diaz M, Casano P,
López-Bermejo A, Marcos MV, Mir I, Moran E and Salvador
C (researchers)
Comparative study of subcutaneous insulin pump,
glargine insulin and NPH in diabetic children aged 0-6 yr.
Phase II
Instituto de Salud Carlos III, Fondo de Investigación
Sanitaria, EC07/90900: 2009-2011
Name of the participants: Torres M (PI), Casano P, Díaz R,
Jaramillo A, Anguita C, Gómez A and Marin S (researchers)
Changes over 4 months (mean ± SEM) in total fat mass (by absorptiometry),
abdominal (abd) subcutaneous (subc) fat (by magnetic
resonance imaging), high-molecular-weight adiponectin (HMW adipo)
and follistatin in short SGA children, before (N=18; open bars)
and during (N=35; shaded bars) growth hormone (GH) treatment.
*p